CytomX Therapeutics Inc (CTMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has a cash flow conversion efficiency ratio of -0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.55 Million) by net assets ($319.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CytomX Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
CytomX Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how CytomX Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CTMX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CytomX Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CytomX Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Groupon Inc
NASDAQ:GRPN
|
0.159x |
|
Beijing Global Safety Technology Co Ltd
SHE:300523
|
-0.018x |
|
Xiangxue Pharmaceutical
SHE:300147
|
-0.899x |
|
Zhejiang Zhaofeng Mechanical and Electronic Co Ltd
SHE:300695
|
0.000x |
|
BEIJ.JINGNENG CL.ERG.HYC1
F:BJ6
|
N/A |
|
JDM Jingda Mach(Ningbo)Co Ltd
SHG:603088
|
0.077x |
|
Charter Hall Social Infrastructure REIT
AU:CQE
|
0.015x |
|
Shanghai Shenda Co Ltd
SHG:600626
|
0.042x |
Annual Cash Flow Conversion Efficiency for CytomX Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of CytomX Therapeutics Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see CytomX Therapeutics Inc (CTMX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $99.01 Million | $-75.59 Million | -0.763x | -100.40% |
| 2024-12-31 | $-456.00K | $-86.23 Million | 189.103x | +15912.09% |
| 2023-12-31 | $-47.45 Million | $-56.03 Million | 1.181x | -8.59% |
| 2022-12-31 | $-85.75 Million | $-110.79 Million | 1.292x | +197.01% |
| 2021-12-31 | $89.38 Million | $-119.03 Million | -1.332x | -96.86% |
| 2020-12-31 | $-7.77 Million | $5.26 Million | -0.676x | +75.39% |
| 2019-12-31 | $51.11 Million | $-140.48 Million | -2.748x | -376.32% |
| 2018-12-31 | $130.88 Million | $-75.52 Million | -0.577x | -123.67% |
| 2017-12-31 | $69.90 Million | $170.37 Million | 2.438x | +9514.09% |
| 2016-12-31 | $78.48 Million | $-2.03 Million | -0.026x | +88.09% |
| 2015-12-31 | $126.07 Million | $-27.41 Million | -0.217x | +46.29% |
| 2014-12-31 | $-78.54 Million | $31.80 Million | -0.405x | -323.89% |
| 2013-12-31 | $-44.28 Million | $-8.01 Million | 0.181x | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell… Read more